Vertebral bone metastasis in breast cancer: A case report

Romanian Journal of Morphology and Embryology

Volumn 52, Issue 3, 2011, Pages 897-905

  Pirici, Elena ^a   Pirici, A ^b   Pǎtranǎ, Nicoleta ^c   Recǎreanu, Felicia ^d   Badulescu F L ^e   Crişan, Anda Elena ^e   Zaharie, Ana Sorina ^c  

^a Emergency County Hospital Valcea   (Romania)

^b Dermato Venereology Section   (Romania)

^c Pathologic Anatomy Section Emergency County Hospital   (Romania)

^d Department of Orthopaedics and Traumatology   (Romania)

^e UNIVERSITY OF MEDICINE AND PHARMACY OF CRAIOVA   (Romania)

Author keywords

Breast cancer; HER2 only positive; Vertebral metastasis

Indexed keywords

AGED; ARTICLE; BONE TUMOR; BREAST TUMOR; CASE REPORT; FEMALE; HUMAN; LUMBAR VERTEBRA; METASTASIS; PATHOLOGY;

AGED; BONE NEOPLASMS; BREAST NEOPLASMS; FEMALE; HUMANS; LUMBAR VERTEBRAE;

EID: 80052648780     PISSN: 12200522     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. [World Health Organisation, Globocan Report, 2008.
2. Suteu O, Ghilezan N, Todor N, Petrache I, Epidemiologia cancerului de san in Romania, Societatea Romana de Cancer, 2010.
3. Guinebretière JM, Menet E, Tardivon A, Cherel P, Vanel D, Normal and pathological breast, the histological basis, Eur J Radiol, 2005, 54(1):6-14.
4. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lønning PE, Børresen-Dale AL, Brown PO, Botstein D, Molecular portraits of human breast tumours, Nature, 2000, 406(6797):747-752.
5. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein Lønning P, Børresen-Dale AL, Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications, Proc Natl Acad Sci U S A, 2001, 98(19):10869-10874.
6. Sørlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, Demeter J, Perou CM, Lønning PE, Brown PO, Børresen- Dale AL, Botstein D, Repeated observation of breast tumor subtypes in independent gene expression data sets, Proc Natl Acad Sci U S A, 2003, 100(14):8418-8423.
7. Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, Jazaeri A, Martiat P, Fox SB, Harris AL, Liu ET, Breast cancer classification and prognosis based on gene expression profiles from a population-based study, Proc Natl Acad Sci U S A, 2003, 100(18):10393-10398.
8. Pusztai L, Ayers M, Stec J, Clark E, Hess K, Stivers D, Damokosh A, Sneige N, Buchholz TA, Esteva FJ, Arun B, Cristofanilli M, Booser D, Rosales M, Valero V, Adams C, Hortobagyi GN, Symmans WF, Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal largescale molecular differences between estrogen-negative and estrogen-positive tumors, Clin Cancer Res, 2003, 9(7):2406-2415.
9. Raica M, Jung I, Cîmpean AM, Suciu C, Mureşan AM, From conventional pathologic diagnosis to the molecular classification of breast carcinoma: are we ready for the change? Rom J Morphol Embryol, 2009, 50(1):5-13.
10. Conforti R, Boulet T, Tomasic G, Taranchon E, Arriagada R, Spielmann M, Ducourtieux M, Soria JC, Tursz T, Delaloge S, Michiels S, Andre F, Breast cancer molecular subclassification and estrogen receptor expression to predict efficacy of adjuvant anthracyclines-based chemotherapy: a biomarker study from two randomized trials, Ann Oncol, 2007, 18(9):1477-1483.
11. [André F, Domont J, Delaloge S, What can breast cancer molecular sub-classification add to conventional diagnostic tools? Ann Oncol, 2007, 18 Suppl 9:ix33-ix36.
12. Suva LJ, Griffin RJ, Makhoul I, Mechanisms of bone metastases of breast cancer, Endocr Relat Cancer, 2009, 16(3):703-713.
13. DJ (ed), Diagnostic immunohistochemistry: theranostic and genomic applications, 3rd edition, Saunders Elsevier, 2010.
14. Coleman RE, Rubens RD, The clinical course of bone metastases from breast cancer, Br J Cancer, 1987, 55(1):61-66.
15. Mundy GR, Metastasis to bone: causes, consequences and therapeutic opportunities, Nat Rev Cancer, 2002, 2(8):584-593.
16. Mantyh PW, Clohisy DR, Koltzenburg M, Hunt SP, Molecular mechanisms of cancer pain, Nat Rev Cancer, 2002, 2(3):201-209.
17. Honore P, Luger NM, Sabino MA, Schwei MJ, Rogers SD, Mach DB, O'Keefe PF, Ramnaraine ML, Clohisy DR, Mantyh PW, Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord, Nat Med, 2000, 6(5):521-528.
18. Coleman RE, Metastatic bone disease: clinical features, pathophysiology and treatment strategies, Cancer Treat Rev, 2001, 27(3):165-176.
19. [RE, Bisphosphonates: clinical experience, Oncologist, 2004, 9 Suppl 4:14-27.
20. Bloom HJ, Richardson WW, Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years, Br J Cancer, 1957, 11(3):359-377.
21. Hortobagyi GN, Theriault RL, Lipton A, Porter L, Blayney D, Sinoff C, Wheeler H, Simeone JF, Seaman JJ, Knight RD, Heffernan M, Mellars K, Reitsma DJ, Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group, J Clin Oncol, 1998, 16(6):2038-2044.
22. Tyczynski JE, Bray F, Parkin DM, Lung cancer in Europe in 2000: epidemiology, prevention, and early detection, Lancet Oncol, 2003, 4(1):45-55.
23. Besbeas S, Stearns MW Jr., Osseous metastases from carcinomas of the colon and rectum, Dis Colon Rectum, 1978, 21(4):266-268.
24. Katoh M, Unakami M, Hara M, Fukuchi S, Bone metastasis from colorectal cancer in autopsy cases, J Gastroenterol, 1995, 30(5):615-618.
25. Nakanishi H, Araki N, Kuratsu S, Narahara H, Ishikawa O, Yoshikawa H, Skeletal metastasis in patients with gastric cancer, Clin Orthop Relat Res, 2004, 423:208-212.
26. Thanapprapasr D, Nartthanarung A, Likittanasombut P, Na Ayudhya NI, Charakorn C, Udomsubpayakul U, Subhadarbandhu T, Wilailak S, Bone metastasis in cervical cancer patients over a 10-year period, Int J Gynecol Cancer, 2010, 20(3):373-378.
27. [Lebret T, Méjean A, Rare locations of metastases from urothelial carcinoma, Prog Urol, 2008, 18 Suppl 7:S289-S297.
28. Papazisis KT, Kontovinis LF, Papandreou CN, Kouvatseas G, Lafaras C, Antonakis E, Christopoulou M, Andreadis C, Mouratidou D, Kortsaris AH, Brain natriuretic peptide precursor (NT-pro-BNP) levels predict for clinical benefit to sunitinib treatment in patients with metastatic renal cell carcinoma, BMC Cancer, 2010, 10:489.
29. Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, Giri DD, Viale A, Olshen AB, Gerald WL, Massagué J, Genes that mediate breast cancer metastasis to lung, Nature, 2005, 436(7050):518-524.
30. Rodríguez-Pinilla SM, Sarrió D, Honrado E, Hardisson D, Calero F, Benitez J, Palacios J, Prognostic significance of basal-like phenotype and fascin expression in nodenegative invasive breast carcinomas, Clin Cancer Res, 2006, 12(5):1533-1539.
31. Koo JS, Jung W, Jeong J, Metastatic breast cancer shows different immunohistochemical phenotype according to metastatic site, Tumori, 2010, 96(3):424-432.
32. Lang JE, Mosalpuria K, Cristofanilli M, Krishnamurthy S, Reuben J, Singh B, Bedrosian I, Meric-Bernstam F, Lucci A, HER2 status predicts the presence of circulating tumor cells in patients with operable breast cancer, Breast Cancer Res Treat, 2009, 113(3):501-507.
33. Kashima K, Oite T, Aoki Y, Takakuwa K, Aida H, Nagata H, Sekine M, Wu HJ, Hirai Y, Wada Y, Yamamoto K, Hasegawa K, Sonoda T, Maruo T, Nagata I, Ohno M, Suzuki M, Kobayashi I, Kuzuya K, Takahashi T, Torii Y, Tanaka K, Screening of BRCA1 mutation using immunohistochemical staining with C-terminal and N-terminal antibodies in familial ovarian cancers, Jpn J Cancer Res, 2000, 91(4):399-409.
34. Gloeckler Ries LA, Reichman ME, Lewis DR, Hankey BF, Edwards BK, Cancer survival and incidence from the Surveillance, Epidemiology, and End Results (SEER) program, Oncologist, 2003, 8(6):541-552.
35. Takeichi M, Inuzuka H, Shimamura K, Fujimori T, Nagafuchi A, Cadherin subclasses: differential expression and their roles in neural morphogenesis. Cold Spring Harb Symp Quant Biol, 1990, 55:319-325.
36. Qureshi HS, Linden MD, Divine G, Raju UB, E-cadherin status in breast cancer correlates with histologic type but does not correlate with established prognostic parameters, Am J Clin Pathol, 2006, 125(3):377-385.
37. De Leeuw WJ, Berx G, Vos CB, Peterse JL, Van de Vijver MJ, Litvinov S, Van Roy F, Cornelisse CJ, Cleton-Jansen AM, Simultaneous loss of E-cadherin and catenins in invasive lobular breast cancer and lobular carcinoma in situ, J Pathol, 1997, 183(4):404-411.
38. Gamallo C, Palacios J, Suarez A, Pizarro A, Navarro P, Quintanilla M, Cano A, Correlation of E-cadherin expression with differentiation grade and histological type in breast carcinoma, Am J Pathol, 1993, 142(4):987-993.
39. Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K, Hess KR, Stec J, Ayers M, Wagner P, Morandi P, Fan C, Rabiul I, Ross JS, Hortobagyi GN, Pusztai L, Breast cancer molecular subtypes respond differently to preoperative chemotherapy, Clin Cancer Res, 2005, 11(16):5678-5685.
40. Hess KR, Anderson K, Symmans WF, Valero V, Ibrahim N, Mejia JA, Booser D, Theriault RL, Buzdar AU, Dempsey PJ, Rouzier R, Sneige N, Ross JS, Vidaurre T, Gómez HL, Hortobagyi GN, Pusztai L, Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer, J Clin Oncol, 2006, 24(26):4236-4244.
41. Cummings MC, Chambers R, Simpson PT, Lakhani SR, Molecular classification of breast cancer: is it time to pack up our microscopes? Pathology, 2011, 43(1):1-8.
42. Thuerigen O, Schneeweiss A, Toedt G, Warnat P, Hahn M, Kramer H, Brors B, Rudlowski C, Benner A, Schuetz F, Tews B, Eils R, Sinn HP, Sohn C, Lichter P, Gene expression signature predicting pathologic complete response with gemcitabine, epirubicin, and docetaxel in primary breast cancer, J Clin Oncol, 2006, 24(12):1839-1845.